Owners, management and financials
CVR: 42805572
DKK 12,258,084
Gross profit
Net result: DKK 937,279
Jonas Karlsen Holding ApS (33,33-49,99%), Daniel Schmidt Holding ApS (33,33-49,99%)
1 more
CVR · view owners
Daniel Schmidt, Jens Rommer
1 more in management
Board: Nicolai Christoffer Bjørndal Hesdorf (chair) and 4 members
CVR · view management
Active
Founded 3 November 2021
CVR · view overview
11 employees
Annual report 2025 · average
Director registered: Jens Rommer
CVR · 01/09/2024
View the full event history
Biobridge Partners ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of Daniel Schmidt, Jens Rommer and Jonas Tobias Karlsen. The board consists of Nicolai Christoffer Bjørndal Hesdorf (chair), Camilla Andrea Harder Hartvig, Daniel Schmidt and Jacob Alexander Peitersen. The company is owned by Jonas Karlsen Holding ApS, Daniel Schmidt Holding ApS and Florian Preis Holding ApS. According to the 2025 annual report, the company had an average of 11 employees. In 2025, the company reported a gross profit of DKK 12,258,084 and a net result of DKK 937,279 compared with DKK 3,470,984 the year before. Equity in the 2025 report amounted to DKK 7,560,642.
Source: annual report 2025, Danish Business Authority
Biobridge Partners ApS demonstrates a solid financial health with a consistent gross profit trend, showing growth from 10.34 million DKK in 2023 to 13.80 million DKK in 2024, before slightly declining to 12.26 million DKK in 2025. Profitability has remained strong, with profits peaking at 3.47 million DKK in 2024, indicating effective cost management and operational efficiency. The company's equity position has also improved, rising from 4.50 million DKK in 2023 to 7.56 million DKK in 2025, reflecting a robust foundation for future growth. However, the lack of disclosed revenue figures raises concerns about transparency and market positioning within the consulting industry. Overall, Biobridge Partners appears well-positioned for continued stability and potential growth in the management consulting sector.
AI-generated summary · Generated 13/08/2026
Selskabets formål er at drive konsulentvirksomhed samt efter bestyrelsens skøn dermed beslægtet virksomhed, og i sin virksomhed og drift at have en væsentlig positiv indvirkning på samfund, miljø, og sundhedsinnovation til gavn for patienter. Selskabet skal via konsulentvirksomhed gøre en positiv forskel for patienter, ved at være katalysator for udvikling og implementering af biotek- og sundhedsinnovation som imødekommer uopfyldte sundhedsbehov. Selskabet skal styre efter at bruge 20% af sin tid på aktiviteter, uden hensyn til profitabilitet, som 1. direkte fremmer banebrydende biotek- og sundhedsinnovation, der imødekommer uopfyldte sundhedsbehov, gennem pro bono-konsulentarbejde, og/eller 2. opbygger selskabets evne til at have en positiv indflydelse på banebrydende biotek- og sundhedsinnovation ved at opbygge viden, kapaciteter og partnerskaber til dette formål. Selskabet skal som udgangspunkt udelukkende servicere life science industrien, herunder den farmaceutiske industri, biotek industrien, relaterede industrier, og sundhedssektoren, samt investorer med interesser i ovennævnte.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 12.3 mio. | 937 t. | 9.9 mio. | 7.6 mio. | 11 | |
| 202401/01/2024 – 31/12/2024 | 13.8 mio. | 3.5 mio. | 11.6 mio. | 9.4 mio. | 8 | |
| 202301/01/2023 – 31/12/2023 | 10.3 mio. | 3.2 mio. | 8.6 mio. | 4.5 mio. | 6 |
Compared to 11.554 companies in Virksomhedsrådgivning og anden ledelsesrådgivning
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Biobridge Partners ApS is 42805572.
Biobridge Partners ApS is owned by Jonas Karlsen Holding ApS, Daniel Schmidt Holding ApS and Florian Preis Holding ApS.
The management of Biobridge Partners ApS consists of Daniel Schmidt, Jens Rommer and Jonas Tobias Karlsen.
The board of Biobridge Partners ApS consists of Nicolai Christoffer Bjørndal Hesdorf, Camilla Andrea Harder Hartvig and Daniel Schmidt, with Nicolai Christoffer Bjørndal Hesdorf as chair.
In 2025, Biobridge Partners ApS reported a gross profit of DKK 12,258,084.
Biobridge Partners ApS had an average of 11 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Biobridge Partners ApS has published its annual report for 2025. Gross profit came to DKK 12,258,084, and the net result was DKK 937,279.
As of August 15, 2025, BDO Statsautoriseret Revisionspartnerselskab has been appointed auditor of Biobridge Partners ApS.
As of August 15, 2025, BDO Holding VII, statsautoriseret revisionsaktieselskab has stepped down as auditor of Biobridge Partners ApS.
As of July 17, 2025, Camilla Andrea Harder Hartvig has joined the board of directors of Biobridge Partners ApS.
Biobridge Partners ApS has published its annual report for 2024. Gross profit came to DKK 13,795,890, and the net result was DKK 3,470,984.
As of January 7, 2025, BDO Holding VII, statsautoriseret revisionsaktieselskab has been appointed auditor of Biobridge Partners ApS.
As of September 1, 2024, Jens Rommer is registered as director of Biobridge Partners ApS.
As of March 22, 2024, Jonas Karlsen Holding ApS is registered as an owner of Biobridge Partners ApS with an ownership share of 33%.
As of March 22, 2024, Daniel Schmidt Holding ApS is registered as an owner of Biobridge Partners ApS with an ownership share of 33%.
As of March 22, 2024, Florian Preis Holding ApS is registered as an owner of Biobridge Partners ApS with an ownership share of 5%.
As of March 11, 2024, Jacob Alexander Peitersen has joined the board of directors of Biobridge Partners ApS.
Biobridge Partners ApS has published its annual report for 2023. Gross profit came to DKK 10,338,446, and the net result was DKK 3,161,736.
Biobridge Partners ApS has published its interim report for the period November 3, 2021 – December 31, 2022.
As of January 2, 2023, Daniel Schmidt is registered as adm. dir. of Biobridge Partners ApS.
As of January 2, 2023, Jonas Tobias Karlsen is registered as director of Biobridge Partners ApS.
As of January 1, 2023, Daniel Schmidt has stepped down as director of Biobridge Partners ApS.
As of January 1, 2023, Jonas Tobias Karlsen has stepped down as adm. dir. of Biobridge Partners ApS.
As of December 19, 2022, Nicolai Christoffer Bjørndal Hesdorf has joined the board of directors of Biobridge Partners ApS.
As of December 19, 2022, Daniel Schmidt has joined the board of directors of Biobridge Partners ApS.
As of December 19, 2022, Jonas Tobias Karlsen has joined the board of directors of Biobridge Partners ApS.
As of December 3, 2021, Daniel Schmidt is registered as director of Biobridge Partners ApS.
As of November 3, 2021, Jonas Tobias Karlsen is registered as adm. dir. of Biobridge Partners ApS.
Biobridge Partners ApS was founded on November 3, 2021.
Companies in the same industry and area
CVR 35411763
CVR 41305878
CVR 16577030
CVR 34484503
CVR 37123315